Clinical Trials Logo

Clinical Trial Summary

This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01660906
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Completed
Phase Phase 4
Start date December 2012
Completion date October 2015

See also
  Status Clinical Trial Phase
Completed NCT01593254 - Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Phase 2
Recruiting NCT03610971 - Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Phase 2
Completed NCT03045120 - Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Recruiting NCT03934372 - Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Phase 1/Phase 2
Completed NCT01850004 - Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Phase 2
Completed NCT01702064 - Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Phase 1
Terminated NCT02627677 - A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Phase 3
Completed NCT01933906 - Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response Phase 1
Completed NCT01914484 - Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Phase 1/Phase 2